Eric Lawitz Selected Research

Interferons

1/2019	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
1/2018	A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
10/2017	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
1/2017	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
2/2016	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
1/2016	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
11/2015	Development of sofosbuvir for the treatment of hepatitis C virus infection.
10/2015	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
9/2015	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
7/2015	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Lawitz Research Topics

Disease

76	Infections 01/2023 - 11/2007
48	Fibrosis (Cirrhosis) 01/2024 - 08/2012
39	Chronic Hepatitis C 01/2019 - 11/2007
17	Hepatitis C 06/2019 - 08/2008
12	Fatigue 05/2019 - 04/2013
11	Anemia 01/2017 - 10/2010
10	Alcoholic Fatty Liver 11/2023 - 10/2018
10	Non-alcoholic Fatty Liver Disease 10/2023 - 01/2018
9	Nausea 11/2023 - 04/2013
8	Liver Diseases (Liver Disease) 01/2021 - 02/2014
7	Headache (Headaches) 05/2019 - 04/2012
6	Diarrhea 11/2023 - 04/2012
5	Pruritus (Itching) 11/2023 - 08/2008
5	Chronic Renal Insufficiency 01/2022 - 06/2016
5	Virus Diseases (Viral Diseases) 01/2018 - 08/2012
4	Inflammation (Inflammations) 10/2023 - 08/2012
4	Liver Cirrhosis (Hepatic Cirrhosis) 09/2023 - 01/2018
4	Persistent Infection 01/2015 - 11/2007
4	Neutropenia 06/2013 - 06/2011
3	Portal Hypertension 12/2023 - 01/2020
3	Body Weight (Weight, Body) 10/2023 - 01/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 07/2014
3	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2019 - 05/2013
2	Vomiting 11/2023 - 06/2014
2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 11/2023 - 01/2019
2	Weight Loss (Weight Reduction) 10/2023 - 01/2023
2	Mental Disorders (Mental Disorder) 01/2021 - 02/2014
2	Chronic Disease (Chronic Diseases) 08/2014 - 06/2014
2	Exanthema (Rash) 07/2013 - 08/2008
1	Cholestasis 11/2023
1	Abdominal Pain (Pain, Abdominal) 11/2023
1	Hepatocellular Carcinoma (Hepatoma) 01/2023

Drug/Important Bio-Agent (IBA)

63	Ribavirin (Virazole)FDA LinkGeneric 01/2023 - 08/2008
33	SofosbuvirIBA 01/2023 - 01/2013
29	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2007
28	InterferonsIBA 01/2019 - 12/2009
22	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 04/2012
13	NucleotidesIBA 01/2019 - 03/2013
9	RNA (Ribonucleic Acid)IBA 01/2023 - 12/2011
9	daclatasvirIBA 06/2020 - 12/2011
8	paritaprevirIBA 05/2019 - 01/2013
8	peginterferon alfa-2a (Pegasys)FDA Link 02/2015 - 08/2008
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2018
7	ledipasvirIBA 10/2020 - 02/2014
7	Ritonavir (Norvir)FDA Link 05/2019 - 01/2013
7	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 09/2015 - 03/2011
6	velpatasvirIBA 01/2023 - 12/2015
6	SimeprevirIBA 06/2020 - 06/2014
6	ombitasvirIBA 05/2019 - 01/2014
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2014
6	grazoprevirIBA 11/2017 - 03/2015
5	glecaprevir and pibrentasvirIBA 01/2021 - 10/2017
5	dasabuvirIBA 05/2019 - 01/2013
5	elbasvirIBA 01/2017 - 03/2015
5	sofosbuvir drug combination ledipasvirIBA 01/2017 - 02/2014
5	telaprevirIBA 09/2015 - 08/2008
4	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamideIBA 02/2016 - 02/2014
4	asunaprevirIBA 02/2016 - 04/2012
3	Alanine Transaminase (SGPT)IBA 10/2019 - 08/2012
3	uprifosbuvirIBA 01/2019 - 11/2017
3	ruzasvirIBA 01/2019 - 11/2017
3	TabletsIBA 01/2017 - 04/2014
3	Erythropoietin FDA Link 06/2016 - 03/2011
3	vaniprevirIBA 06/2014 - 07/2013
2	obeticholic acidIBA 01/2024 - 12/2019
2	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2023 - 01/2023
2	Fatty Acids (Saturated Fatty Acids)IBA 10/2023 - 02/2020
2	semaglutideIBA 10/2023 - 01/2023
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2020 - 10/2019
2	Triglycerides (Triacylglycerol)IBA 02/2020 - 10/2019
2	Drug CombinationsIBA 01/2019 - 01/2011
2	selonsertibIBA 10/2018 - 01/2018
2	simtuzumabIBA 10/2018 - 01/2018
2	CollagenIBA 01/2018 - 01/2018
2	glecaprevirIBA 01/2018 - 10/2017
2	wisteria lectinIBA 01/2018 - 01/2018
2	pibrentasvirIBA 01/2018 - 10/2017
2	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2017 - 01/2017
2	voxilaprevirIBA 01/2017 - 11/2016
2	GS-9451IBA 01/2016 - 07/2014
2	NucleosidesIBA 07/2014 - 02/2014
2	peginterferon alfa-2b (Pegintron)FDA Link 01/2013 - 01/2010
1	saroglitazarIBA 12/2023
1	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA 11/2023
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 11/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2023
1	Alkaline PhosphataseIBA 11/2023
1	Amine Oxidase (Copper-Containing)IBA 11/2023
1	Glucagon-Like Peptide-1 ReceptorIBA 10/2023
1	Glucagon Receptors (Glucagon Receptor)IBA 10/2023
1	aldaferminIBA 09/2023
1	Hormones (Hormone)IBA 09/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023

Therapy/Procedure

32	Therapeutics 10/2023 - 03/2011
6	Duration of Therapy 01/2021 - 02/2015
4	Aftercare (After-Treatment) 10/2018 - 04/2014
3	Liver Transplantation 05/2019 - 01/2017
3	Retreatment 01/2017 - 03/2011
2	Contraindications 11/2015 - 02/2014
2	Drug Tapering 11/2013 - 10/2010